BA
JUNO

BKS Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

BKS Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-6,000
Closed -$231K – 248
2016
Q2 		$231K Buy
+6,000
New +$249K 0.12% 155

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BKS Advisors's JUNO Position: Q3 2016 in Review

BKS Advisors sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2016, closing a stake of 6,000 shares — an estimated $231K sold.

BKS Advisors first reported a position in JUNO in Q2 2016 and held it in 1 quarter. The position peaked at $231K in Q2 2016. 169 funds tracked by Wall St. Rank hold JUNO as of Q3 2016.

  • BKS Advisors reported no remaining Juno Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • BKS Advisors sold 6,000 Juno Therapeutics, Inc. shares in Q3 2016, an estimated $231K.
  • BKS Advisors first reported a position in Juno Therapeutics, Inc. in Q2 2016 and held it in 1 quarter.
  • BKS Advisors's Juno Therapeutics, Inc. position peaked at $231K in Q2 2016.
  • 169 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2016.

Based on BKS Advisors's 13F filing for Q3 2016, filed 9 Nov 2016.